Treatment & Management of Psoriatic Arthritis & Comorbidities

Supported by an educational grant from Amgen

TITLE - Treatment & Management of Psoriatic Arthritis & Comorbidities

TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Rheumatology Pharmacists, Rheumatology Nurses and Nurses

LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy OfficersRheumatology Pharmacists, Rheumatology Nurses and Nurses, along with other healthcare practitioner participants will be able to:

  1. List risk factors that are associated with the development of psoriatic arthritis (PsA) 
  2. Describe PsA-related complications
  3. Identify common comorbidities associated with PsA
  4. Discuss treatment and management strategies for common PsA comorbidities
  5. Explain strategies to improve multidisciplinary communication and education of patients with PsA

Faculty Disclosures:

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Pharmacist continuing education credit

Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hour (0.10CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE #0535-0000-18-023-H01-P

Knowledge Based Activity

Course release date 10/8/2018

Course expires 10/8/2021

Credit Information

Activity Number Credit Amount Accreditation Period
0535-0000-18-023-H01-P 0.1 CEUs October 08, 2018 - October 08, 2021